Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amicus Therapeutics (FOLD) Reports Q2 Loss of $0.34
August 7, 2017 7:03 AM EDTAmicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.34), versus ($0.40) reported last year. Revenue for the quarter came in at $7.2 million, versus $4.2 million reported last year.
179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 On Target to Reach 300 Patients by Year-End 2017Migalastat NDA Submission Targeted for 4Q17Phase 3 EB Topline Data and Complete Phase 1/2 Pompe Data on Track for Late 3Q17John F. Crowley, Chairman and Chief Executive... More
